Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F11%3A10104340" target="_blank" >RIV/00179906:_____/11:10104340 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/11:10104340

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed/21824456" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/21824456</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4088/JCP.10m06529" target="_blank" >10.4088/JCP.10m06529</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)

Popis výsledku v původním jazyce

Our objective was to compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. We used the data acquired in the European First-Episode Schizophrenia Trial, conducted in 14 countries in 498 patients. The subjects joined the study as inpatients and continued with follow-up. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score } 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostilityand (2) that olanzapine would be superior to haloperidol. The primary analysis of hostility indicated an effect of differences between treatments (F(4,889) = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showe

Název v anglickém jazyce

Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)

Popis výsledku anglicky

Our objective was to compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. We used the data acquired in the European First-Episode Schizophrenia Trial, conducted in 14 countries in 498 patients. The subjects joined the study as inpatients and continued with follow-up. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score } 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostilityand (2) that olanzapine would be superior to haloperidol. The primary analysis of hostility indicated an effect of differences between treatments (F(4,889) = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showe

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychiatry

ISSN

0160-6689

e-ISSN

—

Svazek periodika

72

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

955-961

Kód UT WoS článku

000293678600011

EID výsledku v databázi Scopus

—